Table 7.
Effects | MBM | Phy | AB | CALB1 | MUC2 | MUC-5AC | ATP1A1 | ATP13A4 | CACNA1 | CACNB1 | TPCN3 |
---|---|---|---|---|---|---|---|---|---|---|---|
Treatment means | |||||||||||
1 | − | 500 | − | 1.111 | 1.088 | 0.989 | 1.065 | 1.146 | 1.221b,c | 1.202 | 1.098 |
2 | − | 1,500 | − | 1.295 | 1.564 | 1.226 | 1.339 | 1.227 | 1.964a | 1.130 | 0.947 |
3 | − | 500 | + | 2.329 | 1.113 | 1.467 | 1.353 | 0.849 | 1.557a,b | 0.919 | 1.068 |
4 | − | 1,500 | + | 1.938 | 1.354 | 1.450 | 1.275 | 1.283 | 1.549a,b | 0.961 | 1.050 |
5 | + | 500 | − | 0.780 | 1.120 | 0.976 | 1.162 | 1.241 | 1.347b | 1.422 | 1.409 |
6 | + | 1,500 | − | 1.071 | 0.901 | 0.969 | 0.809 | 0.924 | 0.885c | 0.974 | 0.968 |
7 | + | 500 | + | 1.171 | 0.961 | 1.017 | 1.079 | 1.025 | 0.762c,d | 0.965 | 0.876 |
8 | + | 1,500 | + | 1.41 | 1.112 | 1.155 | 1.090 | 1.007 | 1.502b | 1.280 | 1.083 |
2-way interactions | |||||||||||
MBM*Phy | − | 500 | 1.720 | 1.101 | 1.228 | 1.209 | 0.998b | 1.389 | 1.060 | 1.083 | |
− | 1,500 | 1.617 | 1.459 | 1.338 | 1.307 | 1.255a | 1.757 | 1.045 | 0.998 | ||
+ | 500 | 0.975 | 1.040 | 0.997 | 1.121 | 1.133a | 1.055 | 1.194 | 1.142 | ||
+ | 1,500 | 1.242 | 1.007 | 1.062 | 0.949 | 0.966b | 1.757 | 1.127 | 1.026 | ||
Phy*AB | |||||||||||
500 | − | 0.946 | 1.104 | 0.983 | 1.114 | 1.193 | 1.284 | 1.312a | 1.253a | ||
500 | + | 1.750 | 1.037 | 1.242 | 1.216 | 0.937 | 1.159 | 0.942b | 0.972b | ||
1,500 | − | 1.183 | 1.233 | 1.098 | 1.074 | 1.075 | 1.425 | 1.052b | 0.957b | ||
1,500 | + | 1.675 | 1.233 | 1.302 | 1.182 | 1.145 | 1.526 | 1.120a,b | 1.067a,b | ||
Main effects | |||||||||||
MBM | − | 1.668a | 1.280a | 1.283 | 1.258 | 1.126 | 1.573 | 1.053 | 1.041 | ||
+ | 1.109b | 1.024b | 1.029 | 1.035 | 1.049 | 1.124 | 1.160 | 1.084 | |||
AB | − | 1.064b | 1.168 | 1.040 | 1.094 | 1.134 | 1.355 | 1.182 | 1.105 | ||
+ | 1.713a | 1.135 | 1.272 | 1.199 | 1.041 | 1.343 | 1.031 | 1.019 | |||
P > f | |||||||||||
MBM | 0.044 | 0.044 | 0.070 | 0.073 | 0.495 | 0.112 | 0.405 | 0.703 | |||
Phy | 0.764 | 0.194 | 0.523 | 0.764 | 0.689 | 0.364 | 0.751 | 0.378 | |||
AB | 0.021 | 0.788 | 0.096 | 0.390 | 0.408 | 0.965 | 0.244 | 0.449 | |||
MBM × Phy | 0.497 | 0.118 | 0.868 | 0.272 | 0.065 | 0.682 | 0.841 | 0.886 | |||
MBM × AB | 0.302 | 0.632 | 0.389 | 0.959 | 0.809 | 0.920 | 0.559 | 0.091 | |||
Phy × AB | 0.566 | 0.788 | 0.842 | 0.979 | 0.152 | 0.684 | 0.093 | 0.283 | |||
MBM × Phy × AB | 0.628 | 0.225 | 0.467 | 0.147 | 0.904 | 0.085 | 0.212 | 0.258 |
a,b,c Means in the same column within the main effect, 2-way interaction or treatment means with different superscripts are different (P < 0.05).
2-way interaction separated by least square difference; 3-way interaction by Tukey.
Abbreviations: AB, salinomycin 60 ppm in S, G, F; Zn bacitracin 100 ppm in S, G and 50 ppm in F; ATP13A4, ATPase type 13A4; ATP1A1, ATPase Na+/K+ transporting subunit alpha 1; CALB1, calbindin 1; CACNA1, calcium channel; CACNB1, calcium channel, voltage-dependent, beta 1 subunit; MBM, meat and bone meal; MUC2, mucin 2; MUC-5AC, mucin 5; Phy, phytase (Quantum Blue 5G); TPCN3, two-pore calcium channel 3.